水飞蓟宾联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效

发布时间：2018-01-22 07:57

本文关键词： 水飞蓟宾恩替卡韦乙型肝炎肝硬化肝组织学　出处：《世界华人消化杂志》2016年12期 　论文类型：期刊论文

【摘要】：目的:探讨水飞蓟宾联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效.方法:选取2014-01/2015-12武警浙江省总队医院嘉兴分院接受治疗的乙型肝炎肝硬化患者100例,采用随机数表法将100例患者分为实验组和对照组,各50例.给予实验组患者恩替卡韦联合水飞蓟宾治疗,给予对照组患者恩替卡韦治疗.结果:治疗前两组患者的肝功能指标无差异(P0.05),治疗后两组患者的肝功能指标较治疗前均显著改善(P0.05).实验组患者的肝功能情况显示优于对照组患者的肝功能情况(P0.05).治疗前两组患者的肝纤维化指标无差异(P0.05),治疗后两组患者的肝纤维化指标较治疗前均显著改善(P0.05).实验组患者的肝纤维化指标情况显示优于对照组患者的肝纤维化指标情况(P0.05).实验组患者有2例出现口苦、头晕、疲乏、腹部不适等症状,对照组患者有1例出现口苦、腹部不适的症状.两组患者均没有出现过敏等不良反应.结论:恩替卡韦联合水飞蓟宾治疗乙型肝炎肝硬化能够显著改善患者的肝功能、改善患者肝纤维化指标的情况,可以在临床上进一步推广和使用.
[Abstract]:Objective: to investigate the clinical effect of silybin combined with entecavir in the treatment of hepatitis B cirrhosis. A total of 100 patients with hepatitis B cirrhosis received treatment in Jiaxing Branch Hospital of Zhejiang Armed Police Force Hospital, Zhejiang Province, 2014-01 / 2015-12. One hundred patients were divided into experimental group and control group by random number method, 50 cases in each group were treated with entecavir combined with silybin. Results: there was no difference in liver function between the two groups before treatment (P 0.05). After treatment, the liver function indexes of the two groups were significantly improved compared with those before treatment, and the liver function of the patients in the experimental group was better than that of the patients in the control group (P 0.05). There was no difference in hepatic fibrosis between the two groups before treatment (P 0.05). After treatment, the hepatic fibrosis indexes of the two groups were significantly improved compared with those before treatment, and the hepatic fibrosis indexes in the experimental group were better than those in the control group (P 0.05). There were 2 cases of bitter mouth in the experimental group. Dizziness, fatigue, abdominal discomfort and other symptoms, in the control group, there was a case of bitter mouth. Symptoms of abdominal discomfort. There were no adverse reactions such as allergies in both groups. Conclusion: entecavir combined with silybin can significantly improve liver function in patients with hepatitis B cirrhosis. The improvement of liver fibrosis index can be further popularized and used in clinic.
【作者单位】：武警浙江省总队医院嘉兴分院传染科;
【分类号】：R512.62;R575.2
【正文快照】： 0引言由乙型肝炎而引起的肝硬化是肝硬化发生的重要原因之一,严重影响了乙型肝炎患者的生活质量[1].目前临床医师的主要目标为阻止或者延缓乙型肝炎向肝硬化的发展.临床上多采用恩替卡韦来治疗失代偿期乙型肝炎肝硬化,恩替卡韦能够使患者的血清乙型肝炎病毒(hepatitis B virus

【相似文献】